Vertex Pharmaceuticals | VRTX - Interest Income

Stock Price
428.85
Daily Change
-1.44 -0.33%
Monthly
-3.23%
Yearly
-13.62%
Q2 Forecast
421.08

Vertex Pharmaceuticals reported $125.7M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
AbbVie USD 72M 10M Sep/2025
Acadia Pharmaceuticals USD 8.25M 1M Sep/2025
Agios Pharmaceuticals USD 13.37M 1.14M Sep/2025
Alnylam Pharmaceuticals USD 28.68M 1.19M Sep/2025
Arrowhead Research USD 9.05M 1.97M Sep/2025
Biogen USD 31.6M 700K Sep/2025
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Gilead Sciences USD 95M 7M Dec/2025
Incyte USD 30.75M 3.97M Dec/2025
Insmed USD 765K 55K Sep/2024
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.14 237M Mar/2026
Merck USD 96M 27M Sep/2025
Moderna USD 73M 8M Sep/2025
Pfizer USD 0.62 156M Sep/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sanofi EUR 33M 81M Dec/2025
Sarepta Therapeutics USD 8.38M 1.24M Sep/2025
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
United Therapeutics USD 46.4M 4.9M Sep/2025
Vertex Pharmaceuticals USD 125.7M 3.3M Sep/2025